This material may not be published, broadcast, rewritten, or redistributed. Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset . Powered and implemented by FactSet Digital Solutions . Mutual Fund and ETF data provided by Refinitiv Lipper .

Interpreting timescales faster than 0.7 Hz is indeed

We analyzed slowly sampled (1.4 Hz) fMRI data from 1000 healthy

Blood Tests for Alzheimer's Are Here New diagnostic kits aim to revolutionize early screening of the disease, potentially allowing patients to receive treatments--such as monoclonal antibodies--sooner. Last month, The US Food and Drug Administration approved a new blood test for assisting the diagnosis of Alzheimer's disease. Tau is one of two proteins, the other being amyloid, that become malformed and accumulate in the brains of patients with certain types of dementia. It is believed that the buildup of these proteins interferes with the communication of brain cells, leading to these patients' symptoms. The test had already received authorization in July for marketing in Europe and is thus the first early screening system for Alzheimer's for use in primary care settings approved in the planet's two major pharmaceutical markets.

Early detection of Alzheimer's disease (AD) is crucial because its neurodegenerative effects are irreversible, and neuropathologic and social-behavioral risk factors accumulate years before diagnosis. Identifying higher-risk individuals earlier enables prevention, timely care, and equitable resource allocation. We predict cognitive performance from social determinants of health (SDOH) using the NIH NIA-supported PREPARE Challenge Phase 2 dataset derived from the nationally representative Mex-Cog cohort of the 2003 and 2012 Mexican Health and Aging Study (MHAS). Data: The target is a validated composite cognitive score across seven domains-orientation, memory, attention, language, constructional praxis, and executive function-derived from the 2016 and 2021 MHAS waves. Predictors span demographic, socioeconomic, health, lifestyle, psychosocial, and healthcare access factors. Methodology: Missingness was addressed with a singular value decomposition (SVD)-based imputation pipeline treating continuous and categorical variables separately. This approach leverages latent feature correlations to recover missing values while balancing reliability and scalability. After evaluating multiple methods, XGBoost was chosen for its superior predictive performance. Results and Discussion: The framework outperformed existing methods and the data challenge leaderboard, demonstrating high accuracy, robustness, and interpretability. SHAP-based post hoc analysis identified top contributing SDOH factors and age-specific feature patterns. Notably, flooring material emerged as a strong predictor, reflecting socioeconomic and environmental disparities. Other influential factors, age, SES, lifestyle, social interaction, sleep, stress, and BMI, underscore the multifactorial nature of cognitive aging and the value of interpretable, data-driven SDOH modeling.

What's my Alzheimer's risk, and can I really do anything to change it? Can you escape your genetic inheritance, and do lifestyle changes actually make a difference? Daniel Cossins set out to understand what the evidence on Alzheimer's really means for him A few years ago, my dad was diagnosed with Alzheimer's disease, just like his older brother and his mum before him. Slowly, his personality began to ebb away. Now, at the age of 75, his cognitive decline is accelerating: he no longer recognises his granddaughters, for instance, and he lives in a near-constant state of confusion, which means he is losing his independence, too. As I process this loss and try to support my parents, I have become increasingly curious about what my family history means for me.

Neural Information Processing Systems http://nips.cc/

Synthetic clinical data are increasingly important for advancing AI in healthcare, given strict privacy constraints on real-world EHRs, limited availability of annotated rare-condition data, and systemic biases in observational datasets. While large language models (LLMs) can generate fluent clinical text, producing synthetic data that is both realistic and clinically meaningful remains challenging. We introduce DualAlign, a framework that enhances statistical fidelity and clinical plausibility through dual alignment: (1) statistical alignment, which conditions generation on patient demographics and risk factors; and (2) semantic alignment, which incorporates real-world symptom trajectories to guide content generation. Using Alzheimer's disease (AD) as a case study, DualAlign produces context-grounded symptom-level sentences that better reflect real-world clinical documentation. Fine-tuning an LLaMA 3.1-8B model with a combination of DualAlign-generated and human-annotated data yields substantial performance gains over models trained on gold data alone or unguided synthetic baselines. While DualAlign does not fully capture longitudinal complexity, it offers a practical approach for generating clinically grounded, privacy-preserving synthetic data to support low-resource clinical text analysis.

Physical activity is a modifiable lifestyle factor with potential to support cognitive resilience. However, the association of moderate-to-vigorous physical activity (MVPA) intensity, and timing, with cognitive function and region-specific brain structure remain poorly understood. We analyzed data from 45,892 UK Biobank participants aged 60 years and older with valid wrist-worn accelerometer data, cognitive testing, and structural brain MRI. MVPA was measured both continuously (mins per week) and categorically (thresholded using >=150 min/week based on WHO guidelines). Associations with cognitive performance and regional brain volumes were evaluated using multivariable linear models adjusted for demographic, socioeconomic, and health-related covariates. We conducted secondary analyses on MVPA timing and subgroup effects. Higher MVPA was associated with better performance across cognitive domains, including reasoning, memory, executive function, and processing speed. These associations persisted in fully adjusted models and were higher among participants meeting WHO guidelines. Greater MVPA was also associated with subcortical brain regions (caudate, putamen, pallidum, thalamus), as well as regional gray matter volumes involved in emotion, working memory, and perceptual processing. Secondary analyses showed that MVPA at any time of day was associated with cognitive functions and brain volume particularly in the midday-afternoon and evening. Sensitivity analysis shows consistent findings across subgroups, with evidence of dose-response relationships. Higher MVPA is associated with preserved brain structure and enhanced cognitive function in later life. Public health strategies to increase MVPA may support healthy cognitive aging and generate substantial economic benefits, with global gains projected to reach USD 760 billion annually by 2050.